Program
durvalumab
Also written as “Durvalumab”, “MEDI4736” and “MEDI4736 (Durvalumab)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Carcinoma, Hepatocellular · Urinary Bladder Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 8 companies.
Drug pageDurvalumab: every studyMany companies study it; this page follows only the 100 they lead. All 482 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 8643 open or running | phase 4since May 27, 2020 | Sep 14, 2012 | Nov 30, 2026phase 2 · NCT07081633 |
| Bristol-Myers Squibbits history only | 70 open or running | phase 2since Feb 16, 2016 | Nov 25, 2015 | none ahead |
| AbbVieits history only | 20 open or running | phase 2since Feb 27, 2015 | Feb 27, 2015 | none ahead |
| Academic Thoracic Oncology Medical Investigators Consortiumits history only | 10 open or running | phase 2since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Advaxisits history only | 10 open or running | phase 2since Nov 6, 2014 | Nov 6, 2014 | none ahead |
| AGO Researchits history only | 11 open or running | phase 2since Nov 11, 2020 | Nov 11, 2020 | Jan 2028phase 2 · NCT04644289 |
| Boston Scientificits history only | 11 open or running | phase 2since Sep 1, 2021 | Sep 1, 2021 | Jun 2027phase 2 · NCT05063565 |
| Eli Lillyits history only | 10 open or running | phase 1since Oct 7, 2015 | Oct 7, 2015 | none ahead |
Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Biocompatibles UK, Daiichi Sankyo, Parexel, Apices Soluciones S.L., IQVIA Pty, Myriad Genetic Laboratories, PRA Health Sciences and Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jan 11, 2016.
- May 22, 2023Phase 3 study in Liver NeoplasmsNCT05883644 · 111 enrolled · United States, France, Germany and more
- Jun 1, 2023Phase 3 study in Biliary Tract NeoplasmsNCT05924880 · 116 enrolled · China
- Jun 22, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05925530 · 142 enrolled · United States, Austria, Canada and more
- Jul 5, 2023Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT05943106 · 100 enrolled · United States
- Aug 17, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06008093 · 103 enrolled · United States
- Sep 11, 2023Phase 2 study in Carcinoma, HepatocellularNCT06040099 · 58 enrolled · United States
- Oct 23, 2023Phase 3 study in Breast NeoplasmsNCT06103864 · 625 planned · United States, Argentina, Australia and more
- Nov 28, 2024Phase 3 study in Endometrial NeoplasmsNCT06746116 · 45 enrolled · Spain
- Apr 29, 2025Phase 2 study in Urinary Bladder NeoplasmsNCT06960577 · 150 planned · Australia, Brazil, Canada and more
- May 12, 2025Phase 3 study in Small Cell Lung CarcinomaNCT06992609 · 71 enrolled · Spain
- Jun 23, 2025Phase 2 study in Carcinoma, HepatocellularNCT07081633 · 114 enrolled · China, Hong Kong
- Jan 30, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07391670 · 40 planned · Australia, Georgia, Poland and more
- Sep 15, 2026Phase 3 study in GastricNCT07877818 · 140 planned · China
- Oct 9, 2026Phase 4 study in Muscle-Invasive Bladder Cancer (MIBC)NCT07876817 · 50 planned
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07081633
- Jun 30, 2027Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaNCT04550260
- Jul 28, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT06103864
- Aug 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07391670
TargetBeta
“A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Other programs on CD274
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| adebrelimabrule | Jiangsu HengRui Medicine | phase 3 | 51 |
| pumitamig | BioNTech | phase 3 | 34 |
| benmelstobartrule | Sino Biopharmaceutical | phase 3 | 33 |
| retlirafusp alfarule | Jiangsu HengRui Medicine | phase 3 | 20 |
| Anti-PD-L1 Antibody-drug Conjugate HLX43 | Fosun Pharma | phase 3 | 17 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| socazolimabrule | Lee's Pharmaceutical | phase 3 | 9 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| sotiburafusp alfarule | huabo-biopharm-co-ltd | phase 3 | 5 |
| fetrastobart vedotin | Pfizer | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
Studies
The newest 60 of 86 AstraZeneca leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07876817Muscle-Invasive Bladder Cancer (MIBC) | 4 | Not yet recruiting | Jan 31, 2029 | 50 |
| NCT07877818Gastric · China | 3 | Recruiting | Nov 1, 2029 | 140 |
| NCT07391670Carcinoma, Non-Small-Cell Lung · Australia, Georgia, Poland and more | 1 | Recruiting | Aug 30, 2027 | 40 |
| NCT07081633Carcinoma, Hepatocellular · China, Hong Kong | 2 | Active, not recruiting | Nov 30, 2026 | 114 |
| NCT06992609Small Cell Lung Carcinoma · Spain | 3 | Active, not recruiting | Jun 30, 2029 | 71 |
| NCT06960577Urinary Bladder Neoplasms · Australia, Brazil, Canada and more | 2 | Recruiting | Aug 30, 2028 | 150 |
| NCT06746116Endometrial Neoplasms · Spain | 3 | Active, not recruiting | Nov 30, 2028 | 45 |
| NCT06103864Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Jul 28, 2027 | 625 |
| NCT06040099Carcinoma, Hepatocellular · United States | 2 | Active, not recruiting | Jun 30, 2026 | 58 |
| NCT06008093Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Oct 27, 2026 | 103 |
| NCT05943106Non-Muscle Invasive Bladder Neoplasms · United States | 3 | Active, not recruiting | Jun 16, 2025 | 100 |
| NCT05925530Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | Jan 12, 2026 | 142 |
| NCT05924880Biliary Tract Neoplasms · China | 3 | Completed | Feb 7, 2025 | 116 |
| NCT05883644Liver Neoplasms · United States, France, Germany and more | 3 | Active, not recruiting | Mar 30, 2026 | 111 |
| NCT05771480Biliary Tract Neoplasms · United States, France, Germany and more | 3 | Active, not recruiting | Oct 2, 2025 | 142 |
| NCT05629585Breast Neoplasms · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Sep 1, 2027 | 1,174 |
| NCT05557838Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Sep 30, 2026 | 214 |
| NCT05498155Breast Neoplasms · United States, Australia, Austria and more | 2 | Completed | Nov 20, 2024 | 50 |
| NCT05043090Carcinoma, Renal Cell · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 31, 2025 | 148 |
| NCT04960709Urinary Bladder Neoplasms · United States, Argentina, Austria and more | 3 | Active, not recruiting | Mar 2, 2026 | 712 |
| NCT04870112Carcinoma, Non-Small-Cell Lung · United States, New Zealand, Spain and more | 1 | Terminated | Aug 30, 2023 | 18 |
| NCT04774380Small Cell Lung Carcinoma · Bulgaria, Canada, Czechia and more | 3 | Completed | Jun 12, 2023 | 152 |
| NCT04712903Small Cell Lung Carcinoma Extensive Disease · Spain | 3 | Completed | Jun 21, 2023 | 101 |
| NCT04642469Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | May 31, 2023 | 30 |
| NCT04550260Esophageal Squamous Cell Carcinoma · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Jun 30, 2027 | 640 |
| NCT04592913Gastrointestinal Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Dec 20, 2024 | 957 |
| NCT04416633Unresectable Non-small Cell Lung Cancer (NSCLC) · India | 4 | Completed | Oct 27, 2023 | 100 |
| NCT04449861Small Cell Lung Carcinoma Extensive Disease · China | 3 | Completed | Mar 30, 2023 | 166 |
| NCT04385368Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Aug 31, 2023 | 89 |
| NCT04269200Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Jul 8, 2024 | 805 |
| NCT04249362Carcinoma, Non-Small-Cell Lung · United States, France, Italy and more | 2 | Completed | Mar 30, 2023 | 102 |
| NCT04145193Colonic Neoplasms | 2 | Withdrawn | Mar 19, 2024 | 0 |
| NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more | 2 | Active, not recruiting | May 6, 2025 | 247 |
| NCT03875235Biliary Tract Neoplasms · United States, Argentina, Bulgaria and more | 3 | Active, not recruiting | Aug 11, 2021 | 810 |
| NCT03847428Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | May 15, 2026 | 908 |
| NCT03833154Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Active, not recruiting | Oct 31, 2028 | 724 |
| NCT03819465Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more | 1 | Active, not recruiting | May 23, 2023 | 175 |
| NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | Jul 18, 2023 | 189 |
| NCT03794544Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | Jan 13, 2021 | 84 |
| NCT03800134Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Active, not recruiting | Nov 10, 2022 | 825 |
| NCT03830866Locally Advanced Cervical Cancer · United States, Brazil, Chile and more | 3 | Completed | Jan 20, 2022 | 770 |
| NCT03778957Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Active, not recruiting | Sep 11, 2023 | 724 |
| NCT03737643Ovarian Neoplasms · United States, Austria, Belgium and more | 3 | Active, not recruiting | Mar 17, 2025 | 1,407 |
| NCT03732677Urinary Bladder Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Apr 29, 2024 | 1,063 |
| NCT03703297Small Cell Lung Carcinoma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Jan 15, 2024 | 730 |
| NCT03693300Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Completed | Dec 13, 2022 | 117 |
| NCT03682068Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jun 1, 2026 | 1,246 |
| NCT03706690Carcinoma, Non-Small-Cell Lung · China, Hong Kong, India and more | 3 | Active, not recruiting | Jun 23, 2024 | 407 |
| NCT03519971Carcinoma, Non-Small-Cell Lung · Brazil, Czechia, Hungary and more | 3 | Completed | Sep 7, 2023 | 328 |
| NCT03509012Squamous Cell Carcinoma of Head and Neck · United States, Japan, Korea, Republic of and more | 1 | Completed | Dec 31, 2020 | 105 |
| NCT03528694Non-Muscle Invasive Bladder Neoplasms · Australia, Austria, Belgium and more | 3 | Active, not recruiting | Apr 3, 2025 | 1,018 |
| NCT03298451Carcinoma, Hepatocellular · United States, Brazil, Canada and more | 3 | Active, not recruiting | Aug 27, 2021 | 1,324 |
| NCT03164616Non Small Cell Lung Cancer NSCLC · United States, Brazil, Bulgaria and more | 3 | Active, not recruiting | Mar 12, 2021 | 1,186 |
| NCT03084471Diabetes Mellitus, Insulin-Dependent, 12 · United States, Canada, France and more | 3 | Completed | Mar 31, 2020 | 867 |
| NCT03043872Small Cell Lung Carcinoma · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jan 27, 2020 | 987 |
| NCT03003962Non Small Cell Lung Carcinoma NSCLC · United States, Australia, China and more | 3 | Active, not recruiting | Oct 27, 2022 | 669 |
| NCT02978482Advanced Malignancy · China | 1 | Completed | Jan 28, 2018 | 26 |
| NCT02937818Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma · Germany, Hungary, Poland and more | 2 | Completed | Jun 22, 2020 | 72 |
| NCT02734004Stomach Neoplasms · United States, France, Israel and more | 2 | Active, not recruiting | Sep 17, 2021 | 264 |
| NCT02658214Small Cell Lung Carcinoma · Japan, Korea, Republic of | 1 | Completed | Nov 14, 2019 | 32 |
How it is read
Names in the registry
- “Durvalumab”, 55 entries
- “MEDI4736”, 20 entries
- “durvalumab”, 7 entries
- “MEDI4736 (Durvalumab)”, 3 entries
- “MEDI4736 + tremelimumab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 30 studies
- Small Cell Lung Carcinoma, 9 studies
- Carcinoma, Hepatocellular, 8 studies
- Urinary Bladder Neoplasms, 5 studies
- Squamous Cell Carcinoma of Head and Neck, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.